P2.13-08 Phase 1 Study of the AXL Inhibitor DS-1205c in Combination With Osimertinib in Subjects With Metastatic or Unresectable EGFR-Mutant NSCLC.

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1403
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P2.13-43 Phase 1 Study of the Anti-Her3 Antibody Drug Conjugate U3-1402 in Metastatic or Unresectable EGFR-Mutant NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

First-Line Osimertinib in Patients With Treatment-Naive Somatic or Germline EGFR T790M–Mutant Metastatic NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA26.10 CNS Activity of Ramucirumab in Combination With Osimertinib in Patients With Advanced T790m-Positive EGFR-Mutant NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models With EGFR Activating Mutations, T790M Mutation and AXL Overexpression

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

5O_PRA Phase 1b/2 Study of Omaveloxolone in Combination With Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma

Annals of Oncology
MedicineOncologyHematology
2017English

P2.13-23 Osimertinib Treatment Result of Plasma T790M Positive in Different Clinical Failure Modes After First-Line EGFR TKI for EGFR Mutant NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.13-24 Prospective Efficacy of Osimertinib in Circulating Tumour DNA (ctDNA) T790m-Mutant NSCLC Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Third Generation EGFR Inhibitor Osimertinib Combined With Pemetrexed or Cisplatin Exerts Long-Lasting Anti-Tumor Effect in EGFR-mutated Pre-Clinical Models of NSCLC

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2019English

P2.04-27 Ph II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy